February 24, 2022	Mitotech CSO to present at Mitochondria-Targeted Drug Development Summit
January 26, 2022	Mitotech to Host Key Opinion Leader Webinar on Visomitin®: A Potential Treatment for Dry Eye Disease
December 15, 2021	Mitotech granted Orphan Drug Designation by FDA for Visomitin® in LHON
May 6, 2021	Mitotech's focus on opthalmology discussed in Fierce Biotech publication
March 4, 2021	Mitotech CEO Natalia Perekhvatova to present at OIS Dry Eye Innovation Showcase 2021
February 26, 2021	Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease
February 1, 2021	Mitotech to present at LSX Congress 2021
January 11, 2021	Mitotech S.A. To Present at Biotech Showcase Digital 2021 Conference
October 23, 2020	Mitotech to present in Eyecelerator's Retina Livestream organized by AAO and ASCRS
August 25, 2020	Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 – a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
December 12, 2019	Mitotech and Essex Bio-Technology Announce Enrollment in VISTA-2 - a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
October 29, 2018	Mitotech Completes First Patient Visit in VISTA-1 - Phase 2b/3 Clinical Study of SkQ1 for Dry Eye Disease
October 23, 2018	Mitotech Initiates Phase 2b/3 Clinical Trial of SkQ1 Ophthalmic Solution in Patients with Dry Eye Disease in a Co-Development Effort with Essex Bio-Technology
July 19, 2018	Mitotech partners with Essex Bio-Technology for a late-stage clinical program in Dry Eye Disease
October 24, 2017	Mitotech announces new Dry Eye data set supporting SkQ1's novel mechanism of action
April 26, 2017	Mitotech's SkQ1 improved visual acuity in Leber's Hereditary Optic Neuropathy (LHON) patients
April 20, 2017	Mitotech's SkQ1 and its potential for treating age-related disorders discussed in Fierce Biotech publication
March 21, 2017	Mitotech's lead compound significantly increased lifespan of rapidly aging mice
February 10, 2017	Mitotech discusses SkQ1 and Dry Eye Disease in a recent Fierce Biotech article
February 7, 2017	Mitotech will attend the Biotech and Money conference in London, Feb 7-8, 2017
January 20, 2017	Mitotech S.A. Developing a Dry Eye Treatment has been Granted Two U.S. Patents for Pharmaceutical Formulations
September 9, 2016	Mitotech S.A. is granted a patent in anti-aging
July 27, 2016	Mitotech S.A. announces its Ophthalmic Scientific Advisory Board
March 20, 2016	Oxidative stress and dry eye in Review of Ophthalmology
March 1, 2016	Mitotech S.A. to present at ARVO 2016
February 5, 2016	Mitotech CEO to present at the annual BIO CEO and Investor Conference 2016
January 25, 2016	Mitotech S.A. to initiate its first clinical study of a systemic formulation of SkQ1
January 10, 2016	Results of SkQ1 U.S. Phase 2 Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal
December 27, 2015	Results of Mitotech's Multicenter Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal
October 16, 2015	Mitotech S.A. to present at the 2015 Sofinnova Japan Biopharma Partnering Conference
May 3, 2015	Mitotech's posters at ARVO 2015 in Denver, May 3-7
April 23, 2015	Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome
April 21, 2014	Mitotech S.A. announces the initiation of Phase II clinical trial in Dry Eye Patients Utilizing the Controlled Adverse Environment
May 14, 2013	Mitotech completes series of uveitis studies
December 9, 2012	Mitotech's posters at ARVO 2015 in Denver, May 3-7
January 17, 2012	Mitotech initiated pre-clinical program for SkQ1 compound in the U.S.